Fallopian Tube Cancer Clinical Trial
— OPENOfficial title:
Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer
Ovarian cancer patients are often at risk of malnutrition because of weight loss, lack of
appetite and reduced food intake. Being malnourished can contribute to the incidence and
severity of cancer treatment side effects and increase the risk of infection. Currently
patients with advanced ovarian cancer do not receive early nutrition using a feeding tube.
The purpose of this study is to compare enteral nutrition along with standard post-surgery
care against current standard post-operative care alone. This study will see if early
nutrition using a feeding tube has an impact on length of hospital admission, recovery from
surgery, complications from surgery, nutritional status and ultimately a reduction in
treatment costs in people with Advanced Epithelial Ovarian Cancer (EOC). Primary Peritoneal
Cancer (PPC) or Fallopian Tube Cancer. Nutritional support has been shown to ;
- Prevent and treat under-nutrition,
- Enhance anti-tumour treatment effects,
- Reduce adverse effects of anti-tumour therapies,
- Improve quality of life.
Status | Completed |
Enrollment | 109 |
Est. completion date | August 2013 |
Est. primary completion date | August 2013 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients requiring planned primary surgery for suspected or histologically proven advanced ovarian, primary peritoneal cancer or fallopian tube cancer. - Signs of moderate or severe malnutrition - Patient Generated Subjective Global Assessment (PG-SGA) Category B or C and/or a total numerical score of 4 or more in the PG-SGA - Medically fit for primary surgery - Signed written informed consent - Females aged 18 years or older Exclusion Criteria: - Other histological type than ovarian cancer, peritoneal cancer or fallopian tube cancer - Recurrent ovarian cancer, peritoneal or fallopian tube cancer - Pre-existing contraindications to enteral nutrition such as ileus, gastrointestinal ischemia, bilious or persistent vomiting, or mechanical obstruction - Positive urine pregnancy test - Unfit for surgery; serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator) - Participation in other clinical trials that may have an impact on the outcomes of this trial. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Australia | The Wesley Hospital | Auchenflower | Queensland |
Australia | Brisbane Private Hospital | Brisbane | Queensland |
Australia | Greenslopes Private Hospital | Greenslopes | Queensland |
Australia | Royal Brisbane and Women's Hospital | Herston | Queensland |
Australia | Mater Health Services | South Brisbane | Queensland |
Australia | Gold Coast Hospital | Southport | Queensland |
Lead Sponsor | Collaborator |
---|---|
Queensland Centre for Gynaecological Cancer | Cancer Australia Priority-driven Collaborative Cancer Research Scheme, The University of Queensland |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cost outcomes as represented by length of stay and cost effectiveness of enteral feeding / Quality of life | Compare treatment costs and cost effectiveness between early enteral feeding with standard post-operative care versus current standard ost-operative care for advanced epithelial ovarian cancer. Compare quality of life after surgery between women who receive early enteral feeding along with standard post-operative care versus those who receive current standard post-operative care for advanced epithelial ovarian cancer |
End of study | No |
Secondary | length of stay | Length of stay in an intensive care unit or high dependency unit and overall length of hospital stay. | Until discharge from hospital | Yes |
Secondary | Need for inotropic medications and intravenous treatment requirements | Until discharge from hospital | Yes | |
Secondary | Nutritional status 6 weeks after surgery | 6 weeks after surgery | Yes | |
Secondary | Treatment related adverse events | End of study | Yes | |
Secondary | Delay and dose reductions of chemotherapy / quality of life during chemotherapy | End of study | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03393884 -
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
|
Phase 1/Phase 2 | |
Completed |
NCT04546373 -
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
|
||
Active, not recruiting |
NCT05456685 -
IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer
|
Phase 2 | |
Completed |
NCT01442051 -
Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer
|
N/A | |
Completed |
NCT02928549 -
Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study
|
||
Active, not recruiting |
NCT03648489 -
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
|
Phase 2 | |
Not yet recruiting |
NCT04983550 -
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
|
Phase 2 | |
Completed |
NCT02480374 -
Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer
|
Phase 1 | |
Completed |
NCT01899599 -
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
|
Phase 2 | |
Completed |
NCT01610206 -
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
|
Phase 2 | |
Completed |
NCT03480750 -
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01219777 -
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
|
Phase 1 | |
Completed |
NCT01031381 -
Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
|
Phase 2 | |
Completed |
NCT00959582 -
Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)
|
Phase 1 | |
Suspended |
NCT00753480 -
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
|
Phase 1 | |
Completed |
NCT00768144 -
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
|
Phase 2 | |
Completed |
NCT00801320 -
Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer
|
N/A | |
Completed |
NCT00702299 -
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT02349958 -
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
|
Phase 2 | |
Completed |
NCT00390234 -
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
|
Phase 2 |